Where development stands

Phase-gated development sequence

Each phase is gated: work does not advance to the next stage until the preceding technical objectives are met. The sequence is deliberate — formulation stability must be resolved before biological evaluation is meaningful, and biological evaluation must precede any regulatory claim position.

Phase	Objective	Main work	Status
Year 1	Product definition	Supplier qualification; analytical methods; target product profile; initial prototypes; preliminary regulatory assessment; stability program.	In progress
Year 2	Optimization and safety	Inclusion-rate and carrier optimization; palatability and tolerance work; provisional specifications; repeatable pilot batches; intellectual-property assessment.	Planned
Year 3	Controlled validation	Controlled biological evaluation in qualified facilities; statistical analysis; lawful claim set; demonstration batches.	Planned
Year 4	Commercial readiness	Multi-site producer evaluation; contract-manufacturing validation; batch-release controls; technical education.	Planned
Year 5	Scale	Recurring manufacturing and distribution; broader producer adoption; expansion of technical and commercial capacity.	Planned

Development log

Entries are listed most recent first. Dates reflect completion of the stated work.

• 31 August 2026 Company website published Complete

  The feed program, scientific basis, progress log, and regulatory position were published so mills, producers, laboratories, and research collaborators can see the work as it stands and get in touch.

• REPLACE_DATE Producer interest documented for later field evaluation Complete

  A commercial poultry producer in Kentucky provided written interest in participating in practical on-farm evaluation once the formulation has completed the appropriate preceding validation stages. The contemplated farm-level work would assess feed delivery, palatability, production parameters, record-keeping, and operational practicality. It is not a substitute for controlled disease-specific testing.

• REPLACE_DATE Independent technical review completed Complete

  A research faculty member at a Land-Grant university Cooperative Extension program independently reviewed the formulation rationale and the phased validation plan, and identified dosage, bioavailability, stability under feed-manufacturing conditions, and staged validation prior to farm trials as the governing technical priorities. The review assessed methodology; it did not test the product.

• REPLACE_DATE Five-year development and commercialization plan completed Complete

  A phase-gated plan covering formulation, analytical validation, regulatory strategy, manufacturing, staffing, financing, producer engagement, and commercial scale-up, with conservative, realistic, and optimistic operating scenarios and milestone-based financing.

• REPLACE_DATE Formulation-development plan prepared Complete

  Target ingredient specifications, candidate inclusion ranges, feed-matrix compatibility, processing and storage stability, palatability, safety and tolerance, analytical marker requirements, and biological-response parameters defined as the technical questions to be resolved before controlled biological validation.

• REPLACE_DATE Compound selection and mechanistic design completed Complete

  Lablab bean powder, green tea catechins, garlic extract, and ginger extract selected on the basis of peer-reviewed evidence relevant to influenza biology and host defense, suitability for feed delivery, complementary mechanisms, and the feasibility of sourcing and standardization.

What has not yet been established

Stating this plainly is part of how we work. The following remain open and are not claimed:

• The combined four-component formulation has not been shown to reduce susceptibility, viral replication, viral shedding, clinical severity, or mortality in poultry. No such claim is made.
• Final inclusion rates, carrier system, and shelf-life specifications are not yet fixed.
• No controlled biological evaluation, and no live avian influenza challenge study, has been conducted on this formulation.
• Final regulatory classification and the permissible commercial claim set have not been determined.
• The product is not manufactured, marketed, offered for sale, or available for purchase.

Validation conducted only in qualified facilities

Each validation stage is scoped to facilities appropriate to the work. Formulation, marker-assay, and stability work is scoped to commercial analytical laboratories and university feed-testing facilities. Safety, tolerance, palatability, and immune- and antioxidant-response endpoints are scoped to university poultry-research units and contract research organizations operating conventional poultry facilities.